Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Provention_Bio
|
| gptkbp:activities |
modulates immune response
|
| gptkbp:affects |
gptkb:T_cells
may preserve beta-cell function |
| gptkbp:appointed_by |
gptkb:hospital
intravenous infusion two doses patients with high risk of type 1 diabetes |
| gptkbp:approves |
gptkb:2022
gptkb:FDA |
| gptkbp:associated_with |
lower Hb A1c levels
|
| gptkbp:can_lead_to |
reduced need for insulin therapy
|
| gptkbp:clinical_trial |
gptkb:2000
Phase 3 showed efficacy preventing type 1 diabetes in at-risk individuals |
| gptkbp:combatants |
high affinity for C D3
|
| gptkbp:contraindication |
hypersensitivity to teplizumab
|
| gptkbp:developed_by |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:discovered_by |
gptkb:University_of_Chicago
|
| gptkbp:enhances |
quality of life for patients
|
| gptkbp:established |
T cell activation
|
| gptkbp:has_impact_on |
immune system
|
| https://www.w3.org/2000/01/rdf-schema#label |
Teplizumab
|
| gptkbp:increased |
regulatory T cells
|
| gptkbp:indication |
delay onset of type 1 diabetes
|
| gptkbp:influences |
immune tolerance
cytokine production |
| gptkbp:ingredients |
C646 H1008 N178 O198 S4
|
| gptkbp:invention |
patented
|
| gptkbp:involves |
immune modulation
|
| gptkbp:is |
a cure for diabetes
|
| gptkbp:is_associated_with |
improved metabolic control
|
| gptkbp:is_available_on |
prescription medication
|
| gptkbp:is_considered |
a breakthrough therapy
a disease-modifying therapy |
| gptkbp:is_evaluated_by |
safety and efficacy
|
| gptkbp:is_monitored_by |
adverse effects
|
| gptkbp:is_part_of |
diabetes management strategies
clinical guidelines for diabetes treatment |
| gptkbp:is_studied_in |
clinical trials
|
| gptkbp:is_subject_to |
post-marketing surveillance
|
| gptkbp:is_used_for |
treatment of type 1 diabetes
|
| gptkbp:is_used_in |
early intervention in type 1 diabetes
|
| gptkbp:manager |
IV
|
| gptkbp:marketed_as |
brand name Tzield
|
| gptkbp:produced_by |
Chinese hamster ovary cells
|
| gptkbp:reduces |
autoantibody levels
|
| gptkbp:requires |
patient education
|
| gptkbp:research |
reduces insulin dependence
|
| gptkbp:research_areas |
autoimmune diseases
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:side_effect |
headache
nausea fever increased risk of infections infusion reactions |
| gptkbp:suitable_for |
patients with active infections
|
| gptkbp:targets |
C D3 receptor
|
| gptkbp:used_in |
pediatric patients
|
| gptkbp:weight |
148 k Da
|